The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03755167
Recruitment Status : Suspended (Study was suspended due to IPL344 shortage and may resume once drug supply is available. Survival follow-up is still ongoing following participants' consent)
First Posted : November 27, 2018
Last Update Posted : December 8, 2023
Information provided by (Responsible Party):
Immunity Pharma Ltd.

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : January 2026
Estimated Study Completion Date : February 2026